Conference Correspondent

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

By Wayne Kuznar

Conference Correspondent, Drug Updates, ASH

TON - March 2018, Vol 11, No 1

Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate of 41.6% in a phase 1 dose-escalation and expansion clinical trial of patients with relapsed or refractory acute myeloid leukemia and IDH1 mutation, according to data presented at ASH 2017.

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Conference Correspondent, ASH, Multiple Myeloma

TON - March 2018, Vol 11, No 1

An interrupted time-series analysis by David Merola, PharmD candidate, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, and colleagues, showed a significant increase in missed workdays per month after the initial diagnosis of multiple myeloma among patients who received oral or injectable cancer therapy.

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Conference Correspondent, ASH, Palliative Care, Hematologic Cancers

TON - March 2018, Vol 11, No 1

According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.

Emerging Safety Data with Checkpoint Inhibitors

By Phoebe Starr

Conference Correspondent

TON - November 2017, Vol 10, No 6

Immune checkpoint inhibitor therapy is a relatively recent advance in the treatment of several types of cancer and has received much media attention. As healthcare professionals gain more experience with checkpoint inhibitors, it is important for them to understand that the toxicity profiles of these drugs differ from those of chemotherapeutic agents. Read More ›

Psychological Distress in Patients with Cancer Warrants Attention

By Phoebe Starr

Conference Correspondent

TON - November 2017, Vol 10, No 6

The National Comprehensive Cancer Network estimates that at least 33% of patients with cancer have significant psychological distress, and many patients have some levels of distress. Read More ›

Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant

By Phoebe Starr

Conference Correspondent

TON - November 2017, Vol 10, No 6

Patients’ perceptions of worrisome chemotherapy-related side effects have evolved since the 1980s and 1990s, according to a recent survey of women with breast and ovarian cancers that was reported at the 2017 European Society for Medical Oncology Congress. Read More ›

Increased Cancer Risk in Postmenopausal Women with Central Obesity

By Phoebe Starr

Conference Correspondent

TON - November 2017, Vol 10, No 6

Central obesity increases the risk for developing cancer in postmenopausal women more than high body mass index (BMI) and fat percentage, according to a study reported at the 2017 European Society for Medical Oncology Congress. Read More ›

Patients’ Fears of Radiation Side Effects Largely Unfounded

By Phoebe Starr

Conference Correspondent

TON - November 2017, Vol 10, No 6

“Our study shows that women who received modern breast radiation therapy overwhelmingly found the treatment experience far better than expected,” said Susan McCloskey, MD, MSHS, at the 2017 American Society for Radiation Oncology annual meeting. Read More ›

Netupitant plus Palonosetron Noninferior to Aprepitant plus Granisetron in Patients Receiving Highly Emetogenic Chemotherapy

By Li Zhang, MD

Conference Correspondent

TON - November 2017, Vol 10, No 6

“Increasing use of netupitant plus palonosetron would potentially help greater numbers of patients avoid chemotherapy-induced nausea and vomiting, relieving them of the more debilitating complications of anticancer therapy,” said Li Zhang, MD, at the 2017 MASCC Annual Meeting. Read More ›

Patient-Reported Outcomes Influence Radiation Guidelines

By Alice Goodman

Conference Correspondent

TON - September 2017, Vol 10, No 5

Patient-reported outcomes (PROs) are increasingly being incorporated into clinical trial design, which has led to advances that benefit patients. Read More ›

Page 2 of 32

1
2
3
4
5
6
7
8
9
10

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.